Wednesday, 8 February 2017

Gilead's Boom Fades and Bust Will Linger

Company’s great success with hepatitis drug says a lot about drug pricing and risk for the future.

from WSJ.com: Markets http://ift.tt/2lqWtLb
via https://ifttt.com/ IFTTT
Posted by at
Labels:

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)